Some South Korean pharmaceutical companies can expect to jump in sales as they take advantage of global blockbuster drugs losing their patent protection. Dong A, Hanmi, Yuhan and Greencross have recent generic releases to spur that jump, but smaller firms are expected to fall farther behind, according to an analyst. South Korea's pharmaceutical industry has a chance to remake its tarnished image and expand its share of the global market expected to more than double by 2020, with a 9 percent increase expected in South Korea alone. But critics of the industry say it needs to move beyond generics and make new innovative drugs if it is to take advantage of the expected explosion in the demand for medicines. (Click here for more
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
The Belgian drugmaker is boosting its biologics capacity over the pond.
